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Abstract Despite many clinical trials assessing the role of
zinc in major depressive disorder (MDD), the conclusions still
remain ambiguous. The aim of the present clinical study was
to determine and comparison the zinc concentration in the
blood ofMDD patients (active stage or remission) and healthy
volunteers (controls), as well as to discuss its potential clinical
usefulness as a biomarker of the disease. In this study 69
patients with current depressive episode, 45 patients in remis-
sion and 50 controls were enrolled. The zinc concentration
was measured by electrothermal atomic absorption spectrom-
etry (ET AAS). The obtained results revealed, that the zinc
concentration in depressed phase were statistically lower than
in the healthy volunteers [0.89 vs. 1.06 mg/L, respectively],
while the zinc level in patients achieve remission was not
significantly different from the controls [1.07 vs. 1.06 mg/L,
respectively]. Additionally, among the patients achieve
remission a significant differences in zinc concentration be-
tween group with and without presence of drug-resistance in
the previous episode of depression were observed. Also, pa-
tients in remission demonstrated correlation between zinc lev-
el and the average number of depressive episodes in the last
year. Serum zinc concentration was not dependent on atypical
features of depression, presence of psychotic symptoms or
melancholic syndrome, age, age of onset or duration of dis-
ease, number of episodes in the life time, duration of the
episode/remission and severity of depression measured by
the Hamilton Rating Scale for Depression (HDRS), and the
Montgomery-Asberg Depression Rating Scale (MADRS).
Concluding, our findings confirm the correlation between zinc
deficit present in the depressive episode, and are consistent
with the majority of previous studies. These results may also
indicate that serum zinc concentration might be considered as
a potential biological marker of MDD.
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Introduction
Zinc is a crucial element of living organisms, which is involved
in many basic physiological processes (mainly as a cofactor of
over 300 enzymes). This cation is recognized as being impor-
tant for: transcription, translation, DNA repair, proliferation
and maturation of cells, apoptosis, neurogenesis, synaptogen-
esis, neuron growth, or keeping the balance of oxidative and
nitrosative redox potential [see (Jurowski et al. 2014 and
Szewczyk et al. 2011) for review]. Zinc ions also play a role
in the regulation of immune system and inflammation process-
es, influencing the level of some inflammatory cytokines (e.g.
interleukin 6, IL-6; tumor necrosis factor α, TNFα; or
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interleukin 1β, IL-1β) (Szewczyk et al. 2011; Gapys et al.
2014; Maes et al. 1994, 1997, 1999; Maret and Sandstead
2006; Maserejian et al. 2012; Ranjbar et al. 2013; Russo
2011). It has also been shown that Zn concentration declines
during the inflammatory state (Bonaventura et al. 2015).
When compared with other organs, the brain presumably
contains the highest levels of zinc in the body. Within brain,
Zn2+ is nonuniformly distributed and its most abundant in the
hippocampus, amygdala, cerebral cortex, and olfactory bulbs
(Frederickson 1989, Frederickson et al. 2000; Paoletti et al.
2009). There is evidence that zinc deficiency leads to changes
in the central nervous system (CNS) functioning, especially in
the glutamatergic transmission in the limbic system and cere-
bral cortex, which playing an important role in the
etiopathogenesis of depression [see (Mlyniec 2015) for re-
view]. Zinc ions can modulate a number of ligand- and
voltage-gated ion channels, such as gamma-aminobutyric acid
(GABAA) (Frederickson 1989; Marchetti 2014), N-methyl-D-
aspartate (NMDA) (Chen et al. 1997; Szewczyk et al. 2012),
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) and kainate (KA) receptors, and may also affect the
serotonin receptors (Kalappa et al. 2015; Veran et al. 2012;
Satała et al. 2015). By influencing those receptors in the spe-
cific brain areas Zn2+ indirectly modulates synaptic plasticity,
regulate neuronal signal transduction, and other processes,
like memory and learning (Paoletti et al. 2009; Yu et al.
2013; Grabrucker 2014). Furthermore, zinc affects emotional
lability, psychomotor functions, attention (Szewczyk et al.
2011; Swardfager et al. 2013a), irritability (Russo 2011)
and other emotional, executive and cognitive functions
(Szewczyk et al. 2011; Maes et al. 1994, 1997; Swardfager
et al. 2013a; McLoughlin and Hodge 1990; Narang et al.
1991; Salari et al. 2015).
Numerous clinical studies confirm the role of zinc deficien-
cy in the development of depressive symptoms in a course of
major depressive disorder (MDD) (Szewczyk et al. 2011;
Gapys et al. 2014; Maes et al. 1994, 1997; Russo 2011;
Swardfager et al. 2013a, b; McLoughlin and Hodge 1990;
Narang et al. 1991; Gronli et al. 2013; Siwek et al. 2010;
Nguyen et al. 2009; Schlegel-Zawadzka et al. 2000; Siwek
et al. 2013). Some of these show correlation between zinc
deficiency and drug-resistance in patients (Ranjbar et al.
2013; Russo 2011; Swardfager et al. 2013a). It is also proven,
that some antidepressants can influence both the blood and
brain zinc level (Siwek et al. 2010; Nowak et al. 2005). On
the other hand, several case-control trails confirmed antide-
pressant activity of zinc supplementation in the depressed pa-
tients (Szewczyk et al. 2011; Maserejian et al. 2012; Ranjbar
et al. 2013; Lehto et al. 2013; Siwek et al. 2009; Nowak et al.
2003; Salari et al. 2015; LAi et al. 2012).
The aim of this study was to determine the correlation
between symptomatology of MDD, and the serum chang-
es of zinc concentration. The presented results are a part
of the large clinical study named De-Me-Ter (BDepression
– Mechanisms – Therapy ,̂ task 3.2 - Identification of
endogenous marker of depression and therapy effective-
ness) (Siwek et al. 2016a, b; Siwek et al. 2015; Styczeń
et al. 2015).
Materials and methods
Recruitment of the study participants
The study participants (Caucasian men and women) were re-
cruited among the in- and outpatients of the Department of
Psychiatry, University Hospital, Cracow, Poland, in the period
September 21 of 2009 until August 30 of 2013.
Patients fulfilling the DSM-IV-TR criteria for Major
Depressive Disorder (MDD) (both in the active phase of de-
pression, and achieve remission) were recruited to the case-
control study. All the study participants signed an informed
consent and were providedwith detailed information (verbally
and in writing) about the aims and rules of this clinical study.
Each potential study participant had the opportunity to ask
questions about the study before singing the consent and all
those questions were answered by the doctor responsible for
recruitment. The Jagiellonian University Bioethical
Committee has approved this study (decision number KBET
/77/B/2009; dated June 25, 2009).
The most important exclusion criteria were: diagnosis of a
severe psychiatric disorder other than MDD (for example:
schizophrenia, schizoaffective disorder, bipolar disorder), sub-
stance use disorders (excluding addiction to nicotine and caf-
feine), comorbidity of serious physical illness (both acute or
chronic), diagnosis of a severe personality disorders,
breastfeeding, pregnancy or medication which could signifi-
cantly interfere with blood zinc concentration. As severe so-
matic diseases excluding from the study (due to the possibility
of statistically significant change in the concentrations of bio-
markers examined in the De-Me-Ter study) the authors con-
sidered the following: chronic autoimmune and inflammatory
diseases, acute inflammatory or infections present within a
month prior to the recruitment in the study, primary adreno-
cortical insufficiency, renal failure, chronic pancreatitis,
hypopora thyro id i sm, hyper thyro id i sm, pr imary
hypoaldosteronism, cancer, megaloblastic anemia due to iron
deficiency, thalassemia, hemochromatosis, liver cirrhosis,
Wilson’s disease, nephritic syndrome and burns. The additional
excluding criteria was the fact of using by the participants the
following drugs: hydralazine, nonsteroidal anti-inflammatory
drugs (acetylsalicylic acid, ibuprophen, indometacin), tetracy-
clines, florochinolones, calcium, iron, chelating agents or
glucocorticosteroids. All the patients were receiving pharma-
cotherapy with proven efficacy (mono- or polytherapy), in
accordance with the up-to-date treatment guidelines for MDD.
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The group of healthy volunteers consisted of people with no
present and past history of severe and chronic somatic or psy-
chiatric diseases, without history of substance use disorders
(except for caffeine and nicotine abuse), and with no psychiat-
ric disorders in the first-degree relatives. This group was re-
cruited through advertisements on hospital notice boards, by
referral from hospital staff, or their relatives and friends.
The detailed socio-demographic and clinical characteris-
tics of the examined population are presented previously
(Styczeń et al. 2015).
The diagnostic tools
For the measurement of the severity of depressive symptoms
the Montgomery-Asberg Depression Rating Scale –MADRS
(Montgomery and Asberg 1979) and the Hamilton Rating
Scale for Depression – HDRS (Hamilton 1960) were used.
Collection and processing of blood samples. Quantitative
analysis of zinc in the blood serum samples
According to the study protocol max. 9.8 ml of blood was
obtained from each study participant, at the same time of the
day (between 8 and 9 a.m.). Blood was collected from a
brachial vein using the Monovette system (Sarstedt,
Germany). After the cloth formation, the blood was centri-
fuged at 1800 xg for 30 min, and the serum (only non-
hemolysed) was kept frozen at 80 °C until it could be ana-
lyzed. The samples were stored in zinc-free tubes for a max-
imum period of 4 months. The assessment of zinc was per-
formed in specialized laboratory of trace element analysis,
Department of Analytical Chemistry, University of Science
and Technology, Cracow. Serum zinc levels were measured
by a electrothermal atomic absorption spectrometry (ET
AAS) using a PerkinElmer spectrometer model 3110
(USA). The following measurements’ conditions were used:
air – acetylene flame, 285.2 nm wavelength, 0.7 nm slit and
single-element HCL lamps. Gas flow and burner position
were optimized before measurements to achieve high sensi-
tivity. The samples were diluted appropriately to fit into the
linear range (1–50 ng/ml) of calibration curves. Standards
(Zinc standard solution; Merck Millipore Corp., Darmstadt,
Germany) and samples were prepared as water solutions.
Diluted samples were homogenized by means of
sonification. In the case of samples of extremely low volume
(a few microliters) the additive method of sample micro-
dilution was used. The lowest concentration traceability for
zinc was 0.5 μg/L. Despite dilution, no sample pre-treatment
procedures were applied prior to quantitative elements deter-
mination. Depending on the total sample volume, triplicate
determinations were performed. The accuracy of ET AAS
technique was tested by means of recovery analysis, which
for Zn was in the range of 94–99 %. All reagents used were
of analytical grade. The test tubes for Zn were thoroughly
acid washed (0.1 % Nitric acid) and rinsed with double
distilled deionized water.
Statistical methods
The test χ2 was used to analyze the differences between the
quality variables. The Shapiro-Wilk test was performed in
order to evaluate the normal distribution of quantitative data.
Because of absence of the normal distribution of data we used
the Kruskal-Wallis ANOVA or Mann-Whitney U-test.
Correlations between quantitative variables - due to lack of
normal distribution - were analysed with the Spearman’s Rank
correlation.
Results
One-hundred-and-fourteen patients (including 28 men and 86
women) who met the DSM-IV-TR criteria for MDD (69 pa-
tients were in a depressive episode and 45 were in a remission)
were enrolled into the De-Me-Ter case-control study. Among
the recruited group of participants there were patients using
Selective Serotonin Reuptake Inhibitors (SSRI; 63 patients),
Serotonin-Norepinephrine Reuptake Inhibitors (SNRI; 34 pa-
tients), tricyclic antidepressants (TCA; 15 patients), mirtazapine
(5 patients) and also taking atypical antipsychotic drugs
(olanzapine or quetiapine; 15 patients), lithium and lamotrygine
(a total of 5 patients) due to enhance the antidepressant therapy
(Styczeń et al. 2015). The control group consisted of 50 healthy
volunteers (including 14 men and 36 women).
The mean age in the group of patients (49.4 ± 10.7 years)
did not show significant differences from the control group
(45.8 ± 12.4 years), (p = 0.064; Mann-Whitney U-test). There
were also no statistically significant differences between the
sexes in two groups (test χ2; p = 0.64). The percentage of
women in the examined population of patients was 75 %,
and in the control group it was 72 %. In the patient group
there were no differences in the mean zinc concentrations
between women and men subgroups (p = 0.91, Mann
Whitney U-test) (Styczeń et al. 2015).
The zinc concentration in the serum samples of patients in
depressive episode were significantly lower from those ob-
tained in the healthy volunteers group (p = 0.003, Mann
Whitney U-test). However, there were no statistically signifi-
cant differences in zinc levels between patients achieve remis-
sion and control group (p = 0.348, Mann Whitney U-test) or
between depressed stage and remission (p = 0.096, Mann
Whitney U-test) (Table 1).
Among the group of depressed patients there was no sta-
tistically significant difference in zinc levels between patients
with and without the following clinical features: atypical or
psychotic symptoms of depression, melancholic syndrome, or
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drug-resistance (Table 2). However, among the group of pa-
tients in the remission a significant differences in zinc concen-
tration between patients with and without presence of drug-
resistance in the previous episode of depression (p = 0.035,
Mann Whitney U-test) were observed.
Furthermore, our results showed no significant correlations
between zinc levels and age of the patients and some clinical
features (for all: patients in depressive phase, remission and
total group population): duration of the disorder, average num-
ber of hospitalizations in the last year, average number of de-
pressive episodes in the last year, number of total hospitaliza-
tion throughout life, severity of depression measured by HDRS
(a total score), or MADRS (a total score or age of onset) or
duration of current episode severe depression, or remission.
The only significant correlation was obtained between zinc
concentration in patients achieve remission and average num-
ber of depressive episodes in the last year (Table 3).
Discussion
The presented case-control study demonstrated that the serum
zinc levels in patients with depressive episode were signifi-
cantly lower than those obtained in healthy volunteers’ sam-
ples. Moreover, there was no statistically significant differ-
ences in Zn2+ concentration between patients in remission
and healthy volunteers group. The average zinc concentration
in patients achieve remission almost reach the control level,
albeit statistically zinc levels between acute stage of the dis-
ease and remission are not different. Additionally, no signifi-
cant differences between zinc concentration in patients with or
without such clinical features as: atypical features of depres-
sion, drug resistance, presence of psychotic symptoms or mel-
ancholic syndrome were noticed.
Our findings are in a good agreement with most reports,
which demonstrated reduced zinc concentration in the blood
(serum, plasma) of depressed patients (Maes et al. 1994,
1997, 1999; Russo 2011; McLoughlin and Hodge 1990;
Siwek et al. 2010; Schlegel-Zawadzka et al. 2000; Siwek
et al. 2013; Roozbeh et al. 2011; Irmisch et al. 2010;
Amani et al. 2010; Salimi et al. 2008; Wójcik et al. 2006;
Little et al. 1989). However, in some studies blood zinc
concentrations did not differ between depressed patients
and control healthy volunteers group (Ranjbar et al. 2013;
Narang et al. 1991; Gronli et al. 2013; Nguyen et al. 2009;
Manser et al. 1989; Salustri et al. 2010).
Probably the first article which indicated a link between
zinc and depression in the clinical studies was published in
1983 and demonstrated the case of major depressive disor-
der with a low serum zinc level (Hansen et al. 1983). Next
article appeared in 1989. Little et al. examined the zinc
concentration in serum and urine of depressed patients and
demonstrated hypozincemia in 9 out of 30 patients with
mood disorders, however, this study did not include the
control (healthy) group (Little et al. 1989). In the study on
31 Karachi depressed patients, a significantly lower serum
zinc level was shown, but only in depressed women (not in
men) compared to healthy controls (Manser et al. 1989). In
the following year (1990) McLoughlin and Hodge clearly
demonstrated hipozincemia in 14 untreated depressed pa-
tients, compared with 14 healthy controls (McLoughlin and
Hodge 1990).
Our results are similar to this demonstrated by Maes and
colleagues (Maes et al. 1994). In the first study on 48 MDD
patients they showed that not only the zinc level was signifi-
cantly lower in patients group (when compared to healthy vol-
unteers), but also that it was negatively correlated with the
Table 1 Serum zinc concentration [mg/L] inMDD patients, depending
on the current phase of the disease (depression or remission), and healthy
controls. Data are expressed as mean ± SD or Median [Upper/Lower
quartile] (Mann Whitney U-test, *p < 0.01 vs. Control)
Depression Remission Control
Zn concentration
[mg/L]
Mean ± SD
0.89 ± 0.18* 1.07 ± 0.48 1.06 ± 0.34
Median [ Upper/Lower quartile]
0.88
[1.01/0.78]*
0.97
[1.09/0.77]
0.98
[1.22/0.82]
Table 2 Comparison of zinc
serum concentrations [mg/L;
mean (± SD) concentration and
median (upper/ lower quantile)] in
MDD patients with a various
clinical picture of depressive
episodes
Depression Mean ± SD Median
[Upper/Lower quartile]
Mann-Whitney
U-test p
Atypical features With 0.87 ± 0.16 0.83 [0.88/0.75] 0.17
Without 0.99 ± 0.37 0.90 [1.02/0.79]
Melancholic features With 0.92 ± 0.18 0.88 [1.0/0.8] 0.68
Without 1.00 ± 0.40 0.88 [1.02/0.72]
Psychotic syndromes With 0.77 ± 0.13 0.78 [0.88/0.65] 0.09
Without 0.98 ± 0.35 0.88 [1.02/0.79]
Drug-resistant With 0.90 ± 0.20 0.88 [1.07/0.72] 0.94
Without 0.89 ± 0.17 0.87 [1.0/0.79]
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severity of depressive symptoms (Maes et al. 1994). In two
further studies on 31 and 48 patients (respectively) diagnosed
with MDD Maes et al. also confirmed previous observations
Maes et al. 1997, 1999). Additionally, they observed that zinc
level was much lowered in drug-resistant patients (Maes et al.
1997). The our results are also supported by those obtained by
Siwek et al. (2010); Salimi et al. (2008) and Amani et al.
(2010).
The data concerning pre- and postpartum depression
demonstrated relationship between zinc and depression sta-
tus (Wójcik et al. 2006; Roomruangwong et al. 2016), as
well as bipolar depression in which lower zinc level was
characteristic for depressive episode (Siwek et al. 2016b;
Stanley and Wakwe 2002).
Moreover, growing evidence for the valuable augmen-
tation effects of zinc adjunctive therapy coming from clin-
ical studies. The studies demonstrated by Ranjbar et al.
(2013); Russo (2011); Siwek et al. (2009) and Nowak
et al. (2003) showed that zinc supplementation signifi-
cantly reduced depression severity (depression rating
scores) and facilitated the outcome in antidepressant ther-
apy especially in the treatment-resistant patients. Also,
zinc monotherapy reduced symptoms of depression in pa-
tients with coexisting obesity (Solati et al. 2015).
On the other hand, there are several clinical studies that did
not confirmed the presented results. The result obtained by
Gronli et al. on 100 patients aged over 64 years (62 women,
38 men) with different psychiatric diagnoses showed that the
patients without depression were characterized by a higher
deficit of zinc (2013). Similarly, Nguyen et al. noticed in their
observational study on 369 women that there is no correlation
between presence of depressive symptoms and zinc levels
(2009). Also some other groups did not demonstrate alter-
ations in the blood serum of depressed patients (Narang
et al. 1991; Irmisch et al. 2010; Salustri et al. 2010).
The dissimilarity between the data presented in those
reports may origin from the differences in the time of
zinc measurement e.g. depression/remission phase, de-
pression diagnosis – treatment resistant/non-resistant,
previous/current pharmacotherapy, duration of illness,
gender and dietary variability (Swardfager et al. 2013a,
b; Siwek et al. 2013; Nowak 2015).
The mechanisms of the antidepressant activity of zinc may
be connected with its influence (modulation) of the neuro,
immuno and/or oxidative systems [see (Szewczyk et al.
2011; Siwek et al. 2013; Nowak 2015; Maurya et al. 2016;
Tyszka-Czochara et al. 2014) for review].
The obtained results from the presented study confirm the
correlation between zinc deficit present in the depressive ep-
isode, and are consistent with majority of previous studies.
The presented results indicate that zinc blood concentration
might be a biological marker of MDD. Nevertheless the zinc
level in the course of MDD data still remain ambiguous and
should be examined on a bigger populations of depressed
patients to widen the knowledge on the role of zinc in the
pathophysiology of MDD.
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